KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Payables (2016 - 2025)

Historic Payables for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $2.8 billion.

  • Amgen's Payables rose 3218.44% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 3218.44%. This contributed to the annual value of $1.9 billion for FY2024, which is 2000.0% up from last year.
  • Per Amgen's latest filing, its Payables stood at $2.8 billion for Q3 2025, which was up 3218.44% from $3.0 billion recorded in Q2 2025.
  • In the past 5 years, Amgen's Payables ranged from a high of $3.0 billion in Q2 2025 and a low of $1.2 billion during Q3 2021
  • Over the past 5 years, Amgen's median Payables value was $1.4 billion (recorded in 2022), while the average stood at $1.7 billion.
  • As far as peak fluctuations go, Amgen's Payables tumbled by 591.59% in 2023, and later surged by 8704.62% in 2024.
  • Quarter analysis of 5 years shows Amgen's Payables stood at $1.4 billion in 2021, then increased by 15.08% to $1.6 billion in 2022, then grew by 1.15% to $1.6 billion in 2023, then increased by 20.0% to $1.9 billion in 2024, then skyrocketed by 48.74% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q3 2025, $3.0 billion for Q2 2025, and $2.4 billion during Q1 2025.